Drugs / ANX1502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05521269 | Jun 2022 → Nov 2024 | — | Annexon, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANX1502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05521269 ↗ |
| Route | Oral | “Participants will be administrated a single oral dose of ANX1502 at various ascending dose levels or matching placebo.” NCT05521269 ↗ |